Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a leading mental healthcare company specializing in innovative and evidence-based psychedelic-assisted therapies, has announced a change in its Chief Financial Officer (CFO) position. Effective February 18, 2025, Kelvin Yang has been appointed as the new Interim CFO, replacing Melony Valleau, who will be concluding her interim tenure at the end of February.
The Company thanked Ms. Valleau for her contributions and leadership during her tenure as Interim CFO. Mr. Yang brings regulatory and compliance experience to the role, which will be crucial as Numinus navigates its current strategic initiatives. His background in finance, investor relations, and corporate development at The Supreme Cannabis Company, Inc. (previously TSX:FIRE) has equipped him with the skills to lead the finance function, provide leadership across various aspects of operations, and drive key strategic initiatives.
The transition has been approved by the Board of Directors and aligns with the Company's ongoing corporate planning. This change in leadership is part of Numinus' ongoing commitment to strategic planning and corporate development, which is essential for the Company's long-term growth prospects.
Numinus Wellness Inc. is a mental health care company that specializes in innovative and evidence-based psychedelic-assisted therapies. The Company operates through Clinical Research Operations, Canadian Clinic Network, and U.S. Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies. The Canadian Clinic Network segment provides clinical services, including traditional therapy and counseling, ketamine-assisted therapies for depression, and psychedelic-assisted therapies. The U.S. Clinic Network segment offers similar services to patients in the United States.
In conclusion, the transition of the CFO role at Numinus Wellness Inc. brings in a finance professional with relevant experience and a focus on financial stability and growth, aligning with the Company's long-term growth prospects. The smooth transition and support for the outgoing CFO indicate a commitment to maintaining the Company's financial momentum. As Numinus continues to advance its innovative mental health care services and psychedelic-assisted therapies, the new CFO's expertise in finance, investor relations, and corporate development will be instrumental in supporting the Company's strategic objectives.
Comments
No comments yet